MRK
Merck & Company Inc
Merck & Company Inc historical holders
total: 18
Tweedy, Browne Co All Funds (US) Merck & Company Inc transactions over time
- Total transactions:
- 6
- New positions:
- 3
- Sold out:
- 3
- Held since:
- 2018 Q2
- Held for:
- 10 quarters
- Latest activity:
- 2020 Q4
Tweedy, Browne Co All Funds (US) has been an institutional investor in Merck & Company Inc (MRK) since 2016 Q3. According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) doesn't hold any shares. The fund/company first acquired MRK in 2016 Q3, initially purchasing 3,306 shares. Tweedy, Browne Co All Funds (US) later completely sold out the position and reinvested in MRK again in 2018 Q2. Since the initial investment, Tweedy, Browne Co All Funds (US) has made 5 more transactions in this position.
When did Tweedy, Browne Co All Funds (US) exit their MRK position?
Tweedy, Browne Co All Funds (US) no longer holds Merck & Company Inc (MRK). They sold off their entire position in 2020 Q4, closing out an investment that began in 2016 Q3.
When did Tweedy, Browne Co All Funds (US) first invest in MRK?
Tweedy, Browne Co All Funds (US) first invested in Merck & Company Inc (MRK) in 2016 Q3 at the reported quarter-end price of $62.31 per share, acquiring 3,306 shares in their initial purchase.
What is Tweedy, Browne Co All Funds (US)'s average cost basis for MRK?
Based on historical transaction data, Tweedy, Browne Co All Funds (US)'s estimated cost basis for Merck & Company Inc (MRK) is approximately $60.80 per share. This represents their average reported price* across all buy transactions.
Has Tweedy, Browne Co All Funds (US) reinvested in MRK after selling?
Yes, Tweedy, Browne Co All Funds (US) has shown renewed interest in Merck & Company Inc (MRK). After completely selling their position, they reinitiated an investment in 2018 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $60.80
- Weighted AVG sell price:
- $82.88
MRK transactions history by Tweedy, Browne Co All Funds (US)
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q4
|
0.00%
|
$82.88
|
-100% (-3,306)
|
|||
|
2018 Q2
|
0.01%
|
$60.80
|
new
|
|||
|
2017 Q4
|
0.00%
|
$64.13
|
-100% (-3,306)
|
|||
|
2017 Q1
|
0.01%
|
$63.52
|
new
|
|||
|
2016 Q4
|
0.00%
|
$62.31
|
-100% (-3,306)
|
|||
|
2016 Q3
|
0.01%
|
$62.31
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.